PODD Stock Gains Following the Launch of Omnipod 5 in Australia

Insulet Corporation (PODD) recently made its Omnipod 5 Automated Insulin Delivery (“AID”) System commercially available in Australia. Omnipod 5 is available with Dexcom G6 and G7 continuous glucose monitoring (“CGM”) sensor compatibility. The latest development represents a significant step forward in expanding access to its innovative, tubeless Omnipod 5 AID system for more people globally. PODD Stock’s Likely Trend Following the NewsFollowing the announcement on March 18, PODD’s shares climbed 2% to $265. ...